Business Context and Reporting Period
Company: Outlook Therapeutics, Inc. (OTLK)
Filing Type: Form 8-K (Current Report)
Date of Report: May 12, 2026 (Event Date: May 13, 2026)
Reporting Period: This filing reports on specific corporate actions and preliminary financial data as of March 31, 2026.
Key Financial Metrics
- Cash and Cash Equivalents: Approximately $7.7 million as of March 31, 2026 (unaudited and preliminary).
- Recent Capital Raise: The cash balance excludes $4.5 million in net proceeds from a registered direct equity offering completed in April 2026.
- Revenue, Profit, and Margins: The filing text does not provide specific values for revenue, net income, operating margins, or cash flow for the period.
- Debt and Liquidity: No specific debt figures are disclosed in this filing. Liquidity is indicated by the preliminary cash balance and the new equity offering program.
Material Changes and Corporate Actions
- New Equity Offering Program: Entered into an At-The-Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC on May 13, 2026. The Company may sell up to $100,000,000 of common stock through this program.
- Termination of Prior Agreement: Terminated its previous ATM sales agreement with BTIG, LLC, effective May 12, 2026, in connection with the new agreement.
- Commission Structure: The Company will pay H.C. Wainwright a commission of 3% of the aggregate gross proceeds from any sales under the new agreement.
Outlook, Risks, and Management Commentary
- Financial Data Status: Management notes that the $7.7 million cash figure is unaudited, preliminary, and subject to normal quarterly closing processes. Actual results for the three months ended March 31, 2026, may differ materially.
- Forward-Looking Statements: The filing contains forward-looking statements regarding cash positions and future operations, which are subject to risks and uncertainties detailed in the Company's Annual Report on Form 10-K for the year ended September 30, 2025.
- Offering Flexibility: The Company is not obligated to make any sales under the new ATM agreement and may terminate the agreement with five business days' prior written notice.
Investor Verification Checklist
- Verify the final audited cash and cash equivalents balance for the quarter ended March 31, 2026, once the official 10-Q is filed.
- Confirm the total net proceeds received from the April 2026 registered direct equity offering.
- Monitor the utilization of the new $100 million ATM program with H.C. Wainwright for potential dilution.
- Review the full text of the Sales Agreement (Exhibit 10.1) for specific terms regarding price limits or sales conditions.